X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company intends to use the net proceeds from the proposed offering for research and development of its aproprietary LENS integrated intelligence technology for powerful antibody discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: The Benchmark Company
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2023
Details:
The Company intends to use the net proceeds from the proposed offering for research and development of its aproprietary LENS integrated intelligence technology for powerful antibody discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: The Benchmark Company
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 06, 2023
Details:
The net proceeds from the proposed offering for research and development, including its optimize proprietary LENS Integrated Intelligence Technology in silico generated antibodies.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: The Benchmark Company LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 05, 2023
Details:
The companies will jointly conduct research activities to identify and optimize proprietary LENS Integrated Intelligence Technology in silico generated antibodies, targeting an undisclosed target in the TME, as potential therapeutic development candidates.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Xyphos Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2023
Details:
Talem and Libera Bio will jointly develop novel antibodies for use with MPN delivery. The program will leverage BioStrand’s LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio’s Multifunctional Polymeric Nanocapsules (MPN Technology®).
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Libera Bio
Deal Size: $155.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2023
Details:
Under the terms of the agreement, Talem will oversee the development and optimization of the antibodies for each program. OmniAb and Talem will share downstream economics upon potential out-licensing or commercialization of the OmniChicken-derived antibody.
Lead Product(s): OmniChicken-derived Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: OmniAb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2022
Details:
The blinded studies examined the efficacy of IPA’s PolyTope® TATX-03 antibody combination therapy alongside in-house derived formulations of several commercially approved antibodies.
Lead Product(s): TATX-03
Therapeutic Area: Infections and Infectious Diseases Product Name: PolyTope TATX-03
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ludwig-Maximilians-University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
IND-enabling safety evaluations of PolyTope® TATX-03, executed under GLP standards and regulatory guidelines, revealed no in vivo adverse effects during histopathological examination nor any undesirable off-target binding to human biomaterials.
Lead Product(s): TATX-03
Therapeutic Area: Infections and Infectious Diseases Product Name: PolyTope TATX-03
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
IPA's PolyTope® TATX-03 shows continuous validation of potent in vitro neutralizing activity against SARS-CoV-2 variants of concern, as further demonstrated against the Omicron sublineage BA.2.
Lead Product(s): TATX-03
Therapeutic Area: Infections and Infectious Diseases Product Name: PolyTope TATX-03
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
In vivo, IND enabling evaluations of PolyTope® TATX-03, antibody cocktail therapy in the animal model showed that there were no pharmacokinetic aberrations and, injection with TATX-03 is well tolerated – with a significant safety margin and no clinical signs of toxicity.
Lead Product(s): TATX-03
Therapeutic Area: Infections and Infectious Diseases Product Name: PolyTope TATX-03
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
